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Abstract
Background: With the aim to simplify cancer management, cancer research lately dedicated itself
more and more to discover and develop non-invasive biomarkers. In this connection, circulating
cell-free DNA (ccf DNA) seems to be a promising candidate. Altered levels of ccf nuclear DNA
(nDNA) and mitochondrial DNA (mtDNA) have been found in several cancer types and might have
a diagnostic value.
Methods: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in
plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing
between the three study-groups we performed ROC (Receiver Operating Characteristic) curve
analysis. We also compared the levels of both species in the cancer group with clinicopathological
parameters.
Results: While the levels of ccf nDNA in the cancer group were significantly higher in comparison
with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf
mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant:
P = 0.022). The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm;
2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034). Using ROC curve analysis, we were able to
distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker
(cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and
the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%;
specificity: 87%; P < 0.001).
Conclusion:  Our data suggests that nuclear and mitochondrial ccf DNA have potential as
biomarkers in breast tumor management. However, ccf nDNA shows greater promise regarding
sensitivity and specificity.
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Introduction
In several branches of biomedical research the quest for
new disease-related biomarkers has become one of the
main objectives [1-3]. When it comes to discover and
develop new biomarkers, oncology seems to be the most
ambitious field. During the last few years a lot of research
has been done identifying new cancer biomarkers with
the aim to identify high risk individuals, detect cancer at
an early stage, predict outcome, monitor treatment and
screen for disease recurrence [4]. In this respect the focus
is now mainly directed towards the identification of non-
invasive cancer biomarkers [5,6].
In the case of breast cancer, there are only a few non-inva-
sive biomarkers for screening, predicting prognosis and
monitoring that have come to routine clinical application
[7]. Current established methods for routine breast cancer
screening firstly encompass non-invasive methods includ-
ing clinical breast examination and imaging techniques
like mammography and ultrasonography [8]. However,
when pathological changes are suspected these techniques
generally have to be followed by histopathological analy-
sis for which invasive procedures, such as biopsies, are
needed.
Lately, the discovery of circulating cell-free DNA (ccf
DNA) has sparked the interest of scientists as it opens up
a new possibility for non-invasive analysis of tumor
derived genetic material. Both ccf nuclear DNA (nDNA)
and mitochondrial DNA (mtDNA) have become a matter
of investigation and qualitative as well as quantitative
alterations in these two determinants have been impli-
cated in cancer [9]. Changes in the level of ccf nDNA and
mtDNA have been found in plasma and serum of patients
with various cancer types [10,11]. In breast cancer patients
it has been shown that ccf nDNA levels are elevated in
plasma as well as in serum when compared to healthy
controls [12,13]. On the other hand, mtDNA levels were
mostly found to be decreased in breast cancer patients in
comparison to healthy controls [14,15].
To investigate the potential of ccf nuclear and mitochon-
drial DNA as a marker for clinical application we exam-
ined the level of both species in malignant and benign
tumor groups and healthy controls.
Materials and methods
The study was performed at the Laboratory for Prenatal
Medicine and Gynecological Oncology/Department of
Biomedicine, Women's Hospital Basel and approved by
the local institutional review board (Ethic commission
beider Basel). Written consent forms were collected from
all patients who were involved in this study.
Study cohort and sampling procedure
The blood samples used in this study were collected in a
time period from 2005 to 2007 in either the Women's
Hospital of the University of Basel or the Women's Hospi-
tal of Liestal. In total 148 women were included in the
study. Most of the women were European Caucasians. All
blood samples were taken before any surgical interven-
tions or therapeutic treatments. Patients' data (age, tumor
size, lymph node involvement, extent of metastasis, estro-
gen receptor, progesterone receptor and Her2neu - status)
were obtained from the pathological reports. The blood
samples were processed and the DNA was extracted
according to a standardized protocol as previously
described elsewhere [16]. DNA was quantified using a
Nanodrop spectrophotometer (Thermo scientific).
The study cohort (n = 148) was divided into 3 groups: 1)
malignant disease group (n = 52); 2) benign disease group
(n = 26) and 3) healthy control group (n = 70). For groups
1 and 2 the diagnoses were all biopsy-confirmed. The
healthy control group used in this study neither had a his-
tory of cancer nor suffered from any other severe diseases.
qPCR
For the simultaneous quantification of ccf nDNA and
mtDNA from plasma a multiplex qPCR was performed
using the Glyceraldehyd-3-phosphat-dehydrogenase
(GAPDH) and the mtDNA encoded ATPase 8 (MTATP 8)
reference genes.
The gene IDs, the amplicon length, the annealing temper-
ature and the sequence information of primers and
probes for the GAPDH and the MTATP 8 reference genes
are shown in table 1.
qPCR was carried out in 25 μl of total reaction volume
containing 7 μl H2O, 12.5 μl TaqMan® Universal PCR
Master Mix (Applied Biosystems, Branchburg, New Jersey,
USA), 0.75 μl of each of the above mentioned 10 μM
primers (Microsynth, Balgach, Switzerland), 1 μl of a 5
μM FAM-labeled MTATP 8-probe and 0.5 μl of a 5 μM
VIC-labeled  GAPDH-probe (both probes from Applied
Biosystems, Rotkreuz, Switzerland). For each reaction 1 μl
of DNA was added. qPCR was performed using the ABI
PRISM 7000 Sequence Detection System (Applied Biosys-
tems, Branchburg, New Jersey, USA) under the following
conditions: an initiation step for 2 minutes at 50°C is fol-
lowed by a first denaturation for 10 minutes at 95°C and
a further step consisting of 40 cycles of 15 seconds at 95°C
and 1 minute at 60°C.
Data collection and processing
The threshold cycle (Ct) values were obtained by the ABI
Prism 7000 software. Each sample was analyzed in dupli-Molecular Cancer 2009, 8:105 http://www.molecular-cancer.com/content/8/1/105
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cate and one negative control was included in every run.
For calibration a standard calibrator curve with known
genomic DNA concentrations ranging from 3.125 × 104
to 10 pg/μL with a dilution factor of 5 (including 31250,
6250, 1250, 250, 50 and 10 pg/μL) was used. The effi-
ciency of the multiplex assay for amplifying both nDNA
and mtDNA simultaneously was measured in our previ-
ous study using standard curves generated by dilution
series [17]. The standard curves had average slopes at
approximately -3.3 (~100% efficiency). GAPDH  and
MTATP8 levels were normalized by data obtained from
the amplification of HPLC-purified single-stranded syn-
thetic DNA oligonucleotides (Microsynth) specifying a
97-bp  GAPDH  amplicon and a 79-bp MTATP8  gene
amplicon with concentrations ranging from 5 × 107 copies
to 5 × 102 copies. The concentrations of ccf nDNA were
calculated according to the standard curves, using known
concentration of human genomic DNA. The results were
expressed as genome-equivalent (GE) per mL of plasma
by using the conversion factor of 6.6 pg of DNA per cell.
Genome equivalents were calculated as follows:
For the calculation of the concentration (c) in genome
equivalents (GE/mL) the DNA quantity (Q) obtained by
qPCR was multiplied with one fraction consisting of the
volume of eluted DNA (VDNA; 80 μl/sample) divided by
the sample volume used for PCR (VPCR; 2.5 μl/reaction)
resulting in a factor of 32 and with another fraction con-
sisting of the unit (1 ml) divided by the volume of
extracted plasma (VEX = 400 μl) resulting in a factor of 2.5.
The content of mtDNA was calculated using the delta Ct
(ΔCt) of an average Ct of mtDNA and nDNA (ΔCt =
CtnDNA - CtmtDNA) in the same well as an exponent of
2 (2ΔCt). Relative quantities of ccf mtDNA could be esti-
mated using an equation of GE (nDNA) × fold-change
mtDNA and expressed also as GE per mL of plasma.
Statistical Analysis
All statistical analyses were performed using SPSS 17.0
(SPSS Inc., Chicago, USA). The normality distribution of
the data was determined using the Shapiro-Wilk-Test. The
data were not normally distributed. For comparison of ccf
nDNA and mtDNA levels between the three groups
(malignant disease group, benign disease group and
healthy control group) the Mann-Whitney-U-Test was
performed. For the comparison of the ccf nDNA and
mtDNA levels with other established prognostic factors
the Mann-Whitney-U-Test and the Kruskal-Wallis-Test
were used. P-values ≤ 0, 05 were considered statistically
significant.
Results
Comparison of plasma ccf nDNA and mtDNA levels 
between the three study-groups
We compared the levels of plasma ccf nDNA and mtDNA,
analyzed by multiplex real-time PCR, between the malig-
nant disease group, the benign disease group and the
healthy control group. The level of ccf nDNA in the malig-
nant disease group was significantly higher in comparison
with the benign disease group (4678 vs. 1359, Mann-
Whitney: P < 0.001) and the healthy control group (4678
vs.1298, Mann-Whitney: P < 0.001). No significant differ-
ence could be found in the level of nDNA between the
benign disease group and the healthy controls (1359 vs.
1298 Mann-Whitney: P = 0.830).
In contrast to the ccf nDNA determination, a decreased
level of ccf mtDNA was found in the malignant disease
group when compared with the healthy control group
cQV V V DNA PCR EX =× × // 1
Table 1: Quantitative PCR (qPCR) for GAPDH and MTATP8
Gene Gene ID Sequences of primers and probes (5' → 3') Length of primer/probe Amplicon lengths (bp)
GAPDH 2597 Forward CCC CAC ACA CAT GCA CTT ACC 21 97
Reverse CCT AGT CCC AGG GCT TTG ATT 21
Probe (MGB) TAG GAA GGA CAG GCA AC (VIC) 17
MTATP8 4509 Forward AAT ATT AAA CAC AAA CTA CCA CCT ACC 27 78
Reverse TGG TTC TCA GGG TTT GTT ATA 21
Probe (MGB) CCT CAC CAA AGC CCA TA (FAM) 17
Quantitative PCR (qPCR) for GAPDH and MTATP8 was carried out in a total reaction volume of 25 μl containing 7 μl H2O, 12.5 μl TaqMan® 
Universal PCR Master Mix, 0.75 μl of each of the shown 10 μM primers, 1 μl of a 5 μM FAM-labeled MTATP 8-probe and 0.5 μl of a 5 μM VIC-
labeled GAPDH-probe and 1 μL of template. The reaction was performed at the following conditions: initiation for 2 minutes at 50°C, followed by a 
first denaturation for 10 minutes at 95°C and a further step consisting of 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.Molecular Cancer 2009, 8:105 http://www.molecular-cancer.com/content/8/1/105
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(205013 vs. 522115, Mann-Whitney; P = 0.022) and the
benign disease group (205013 vs. 73977; Mann-Whitney:
P < 0.001). However, in the benign disease group the level
of ccf mtDNA is even significantly lower than in the
malignant disease group (73977 vs. 205013; Mann-Whit-
ney: P < 0.001). The median of plasma ccf nDNA and
mtDNA in the three study groups is shown in Table 2. The
comparison of the ccf nDNA and mtDNA levels between
the study groups is depicted in Fig. 1.
Correlation between the level of plasma ccf nDNA and 
mtDNA with clinicopathological parameters
For the malignant disease group, the association between
the level of ccf DNA and other established clinical param-
eters, including tumor size, lymph node involvement,
extent of metastasis and the status of estrogen receptor
(ER), progesterone receptor (PR) and Her2/neu were ana-
lyzed.
Association between plasma ccf DNA level and tumor size 
in the malignant disease group
The level of ccf nDNA was significantly lower in patients
with breast cancer with a tumor size of less than two cen-
timeters (<2 cm; n = 21) than in those with a tumor size
between 2 and 5 centimeters (>2 cm<5 cm; n = 25) (2250
vs. 6658; Mann-Whitney: P = 0.034). Only four patients
with a tumor size of more than five centimeters (>5 cm)
were recruited. There was no significant difference in the
level of ccf nDNA between patients with a tumor size of
more than five centimeters (>5 cm) and a tumor size from
2 to 5 centimeters (2 cm-5 cm). No correlation between
the levels of ccf mtDNA and tumor size could be found.
The correlation between ccf nDNA level and the tumor
size is depicted in Fig. 2.
Association between plasma ccf DNA level and lymph 
node involvement, extent of metastasis, receptor status of 
ER, PR and Her2/neu amplification in the malignant 
disease group
In the malignant disease group no statistical significance
in the level of ccf nDNA nor mtDNA between node nega-
tive and node positive patients, extent of metastasis and
receptor status of ER, PR and Her2/neu amplification
could be found.
The applicability of plasma ccf nDNA and mtDNA as 
marker for the discrimination between the three study 
groups
To evaluate the applicability of ccf plasma nDNA and
mtDNA as a marker for distinguishing between malignant
disease group, benign disease group and healthy control
group, we performed ROC (Receiver Operating Character-
istic) curve analysis. For the identification of the optimal
cut-off point we used the Youden index (J). J is the maxi-
Boxplot for the comparison of the ccf nDNA and mtDNA levels between the study- groups Figure 1
Boxplot for the comparison of the ccf nDNA and mtDNA levels between the study- groups. A) Boxplot for com-
parison of ccf nDNA levels between the malignant disease group and the healthy control group. Level of ccf nDNA in the can-
cer group was significantly higher in comparison with the healthy control group (P < 0.001). As no significant difference was 
found in the level of ccf nDNA between the benign disease group and the healthy controls the comparison is not shown in the 
figure. B) Boxplot for comparison of ccf mtDNA levels between the tumor group (including the malignant and benign cases) 
and the healthy control group (P < 0.001). Decreased levels of ccf mtDNA was found in both, the benign disease group and the 
malignant disease group, when compared to the healthy control group. (* significant correlation; Mann-Whitney-U-Test).Molecular Cancer 2009, 8:105 http://www.molecular-cancer.com/content/8/1/105
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mum vertical distance between the ROC-curve and the
diagonal reference line and is defined as J = maximum
(sensitivity) + (specificity) - 1. The Youden index allows
the selection of an optimal cut-off point under the
assumption that sensitivity and specificity are equally
weighted [18].
ROC curve analysis using ccf nDNA for the discrimination 
between the malignant disease group and the healthy 
control group
Level of ccf nDNA in the malignant disease group was sig-
nificantly higher in comparison with the healthy control
group, but no significant difference was found in the level
of ccf nDNA between the benign disease group and the
healthy controls. For discriminating between the malig-
nant disease group and the healthy control group, an opti-
mal cut-off point was indicated at 1866 GE/ml for plasma
ccf nDNA with a sensitivity of 81% and a specificity of
69% (AUC = 0.80, P < 0.001, 95% confidence interval =
0.732-0.885). The ROC-curve for discrimination between
the malignant disease group and the healthy control
group using ccf nDNA is shown in Fig. 3.
ROC curve analysis using ccf mtDNA for the discrimination 
between the breast tumor group and the healthy control 
group
Decreased levels of ccf mtDNA was found in both the
benign disease group and the malignant disease group
when compared to the healthy control group. For discrim-
inating between the breast tumor group (malignant and
benign) and the healthy control group an optimal cut-off
point was indicated at 463282 GE/ml for ccf nDNA with
a sensitivity 53% and a specificity of 87% (AUC = 0.68, P
< 0.001, 95% confidence interval = 0.589-0.768). The
ROC-curve for discrimination between the breast tumor
group and the healthy control group using ccf mtDNA is
shown in Fig. 3.
Discussion
According to our knowledge, our study is the first to find
increased levels of ccf nDNA and simultaneously
decreased levels of ccf mtDNA in plasma samples from
patients with breast tumor compared to healthy controls.
The former shows a probable diagnostic value in discrim-
inating between breast cancer and healthy controls with a
sensitivity of 81% and specificity of 69%, the latter reveals
possible relevance in distinguishing between breast
tumors (malignant and benign) and normal controls with
a sensitivity of 53% and specificity of 87%.
For ccf nDNA, our previous studies indicated that in com-
parison with other potential circulating biomarkers
involved in malignancy, such as nucleosomes, vascular
endothelial growth factor (VEGF) and its soluble receptor
(sVEGFR1), the ccf DNA showed more sensitivity and spe-
cificity in discriminating between breast cancer and nor-
mal controls [19,20]. Recently, Diehl et al, explored the
possibility of using ccf tumor derived DNA for the man-
agement of colorectal cancer [21]. Patients with detectable
ccf tumor DNA suffered from relapse, whereas subjects
without ccf tumor DNA did not experience tumor recur-
rence. The ccf tumor DNA detection seems to be more reli-
able for predicting relapse than the standard biomarker,
carcinoembryonic antigen (CEA), used for the manage-
ment of colorectal cancer [22]. It was also reported that
Table 2: Concentrations (GE/mL) of plasma ccf nDNA and ccf mtDNA in the 3 study-groups; expressed as median.
Group Total no. of patients Age
(mean ± S.D.)
Median Ccf nDNA(GE/mL) Median Ccf mtDNA (GE/mL)
Malignant disease group 52 64 ± 15 4678 205013
Benign disease group 26 41 ± 16 1359 73977
Control group 70 53 ± 14.6 1298 522115
Scatterplot for correlating levels of ccf nDNA between  breast cancer patients with a tumor size > 5 cm; (n = 4), >2  cm<5 cm; (n = 25) and < 2 cm; (n = 21) Figure 2
Scatterplot for correlating levels of ccf nDNA 
between breast cancer patients with a tumor size > 5 
cm; (n = 4), >2 cm<5 cm; (n = 25) and < 2 cm; (n = 
21). Significant difference in the levels of ccf nDNA could be 
found between tumors with a tumor size of >2 cm<5 cm and 
tumors with a tumor size of < 2 cm (P = 0.034). For the 
group of the tumor size > 5 cm, only 4 cases were recruited. 
(* significant correlation; Mann-Whitney-U-Test).Molecular Cancer 2009, 8:105 http://www.molecular-cancer.com/content/8/1/105
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the levels of ccf DNA could be changed after therapy in
breast cancer [23,24]. The observations suggest that deter-
mination of ccf DNA in cancer may prove a useful tool in
the management of the condition.
In this study, we found high levels of ccf plasma DNA
related to tumor size. This finding can be supported by
investigations in the field of prenatal medicine. Placenta
has been regarded as "pseudomalignant" and placental
derived ccf fetal DNA in maternal circulation can be used
for risk-free prenatal diagnosis [25-27]. The concentration
of placental derived ccf fetal DNA in maternal blood
increases with the progress in gestational weeks and with
respect to placental size [28]. Using fetal specific DNA
sequences, ccf fetal DNA could be detected from the 5th
gestational week, and the results were reliable by the 8th
gestational week with an accuracy of 100% in fetal DNA
determination [29,30]. The results imply that by using
tumor specific genetic alterations as marker, tumor
derived ccf DNA may be detectable at an early stage with
confined tumor growth and size.
For mtDNA, both down-or up-regulation in cancer
patients has been shown in the past, and many attempts
to explain both events have been made. While up-regula-
tion of mtDNA in cancer patients was only demonstrated
in a few cases [31], many studies including this one found
decreased mtDNA levels in cancer patients [32,33]. One
explanation for lower mtDNA copy numbers in cancer
patients might be ascribed to mutations or deletions
occurring as a consequence of exposure of mtDNA to reac-
tive oxygen species (ROS) which are a by-product of respi-
ration and oxidative phosphorylation. Especially in the D-
Loop region which controls replication and transcription
of mtDNA, such mutations and deletions may lead to
changes in transcription and replication rate and finally
result in a decrease of mtDNA levels in cancer patients
[34]. In this study we found lower levels of mtDNA in the
benign group when compared with the cancer group. In
benign tumors depletion of mtDNA could be a mecha-
nism of tumor cells to escape apoptosis and to finally pro-
mote cancer progression [35]. On the other hand, the
relative increase of mtDNA levels in the cancer group
compared to the benign disease group might be a com-
pensatory mechanism of the cells to respond to the
decline in respiratory function [36].
We showed that levels of ccf nDNA where significantly
elevated in breast cancer patients in comparison with a
benign disease group and a healthy control group, while
levels of ccf mtDNA were significantly elevated in the
breast tumor group (malignant and benign) when com-
pared to the healthy control group. Regarding ccf nDNA
levels, our results are confirmed by the findings of other
studies which also found altered levels of ccf nDNA in
cancer patients. For ccf mtDNA however, both down- as
well as upregulation of ccf mtDNA levels in cancer
patients have been reported and therefore grant further
investigations of mtDNA content in different cancer and
ROC curves using ccf nDNA and mtDNA for discriminating between the study-groups Figure 3
ROC curves using ccf nDNA and mtDNA for discriminating between the study-groups. A) ROC curve of ccf 
nDNA for discriminating between the cancer group and the healthy control group (sensitivity = 81%; specificity = 69%). B) 
ROC curve of ccf mtDNA for distinguishing between the tumor group and the healthy control group (sensitivity = 53%; specif-
icity = 87%).Molecular Cancer 2009, 8:105 http://www.molecular-cancer.com/content/8/1/105
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tumor types, in order to clearly establish whether mtDNA
levels are cancer type or tumor specific.
To conclude, both ccf nDNA and mtDNA levels allowed
for discrimination between the different study groups.
While ccf nDNA could be used for discriminating between
patients with breast cancer and healthy controls, ccf
mtDNA could be used for distinguishing between patients
with breast tumors (malignant and benign) and healthy
controls. Altogether this suggests that ccf nDNA has
potential as a cancer specific biomarker, whereas ccf
mtDNA may rather serve as a tumor biomarker.
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